adenine has been researched along with fludarabine in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.71) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (5.71) | 29.6817 |
| 2010's | 23 (65.71) | 24.3611 |
| 2020's | 8 (22.86) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, P; Plunkett, W | 1 |
| Avramis, VI; Plunkett, W | 1 |
| Bauta, WE; Cantrell, WR; Schulmeier, BE | 1 |
| Cervasi, B; Engram, J; Fraternale, A; Lawson, B; Magnani, M; Menotta, M; Paiardini, M; Perno, CF; Piedimonte, G; Serafini, S; Silvestri, G; Staprans, SI | 1 |
| Almasan, A; Hill, BT; Kalaycio, M; Mazumder, S; Sharma, A; Singh, K | 1 |
| Burke, RT; Druker, BJ; Loriaux, MM; Prins, RC; Spurgeon, SE; Tyner, JW | 1 |
| Aoki, S | 1 |
| Brown, JR; O'Brien, SM; Porter, DL | 1 |
| Byrd, JC; Flynn, JM; Johnson, AJ; Jones, JJ; Woyach, JA | 1 |
| Byrd, JC; Gordon, A; Guinn, D; Hertlein, E; Jaglowski, S; Johnson, AJ; Larson, R; Lin, TS; Maddocks, K; Marcucci, G; Ruppert, AS; Woyach, J | 1 |
| Bergmann, M; Wendtner, CM | 1 |
| Guillen, KP; Harrison, RG; Kurkjian, C; Restuccia, A | 1 |
| Assaily, W; Bence-Bruckler, I; Chamakhi, I; Christofides, A; Owen, C; Robinson, S; Toze, C | 1 |
| Treon, SP | 1 |
| Ave, E; Castelli, M; Chiodin, G; Facco, M; Frezzato, F; Gattazzo, C; Giorgi, CA; Lessi, F; Martini, V; Piazza, F; Semenzato, G; Severin, F; Trentin, L; Trimarco, V; Visentin, A; Zambello, R | 1 |
| Burger, JA; Estrov, Z; Ferrajoli, A; Jain, N; Keating, MJ; O'Brien, SM; Thompson, PA; Wang, X; Wierda, WG; Xiao, L | 1 |
| Brown, JR; Hallek, MJ; Pagel, JM | 1 |
| Aurran-Schleinitz, T; Birsen, R; Bonnet, C; Boubaya, M; Choquet, S; Cymbalista, F; Delarue, R; Dietrich, PY; Dupuis, J; Fahri, J; Lamy, T; Leblond, V; Lemal, R; Lepretre, S; Levy, V; Michallet, AS; Re, D; Troussard, X; Wanquet, A; Ysebaert, L | 1 |
| Baculea, S; Cote, S; Diels, J; Van Sanden, S | 1 |
| Baculea, S; Côté, S; Diels, J; Dorman, E; Fahrbach, K; Sanden, SV; Xu, Y | 1 |
| Jain, N | 1 |
| Wierda, WG | 1 |
| Wendtner, CM | 1 |
| Barr, PM; Barrientos, J; Braggio, E; Cashen, AF; Coutre, SE; Erba, H; Hanson, CA; Jelinek, DF; Kay, NE; Leis, JF; Little, RF; Litzow, M; Mato, AR; Mullane, MP; O'Brien, S; Shanafelt, TD; Singh, AK; Stone, RM; Tallman, M; Wang, XV; Zhang, CC | 1 |
| Stirrups, R | 1 |
| Bachy, E; Baseggio, L; Besson, H; Callet-Bauchu, E; Diels, J; Doubek, M; Garside, J; Healy, N; Hermans, R; Iraqi, W; Lundbom, J; Lysak, D; Panovska, A; Pick-Lauer, C; Salles, G; Simkovic, M; Smolej, L; Spacek, M; Urbanova, R | 1 |
| Al Tourah, AJ; Bruyere, H; Dueck, G; Galbraith, P; Gerrie, AS; Hardy, E; Hrynchak, M; Huang, SJ; Noble, MC; Ramadan, KM; Sehn, L; Toze, CL; Tsang, P; Tucker, T; Young, S | 1 |
| Suzumiya, J; Takizawa, J | 1 |
| Allain, EP; Bat, V; Caron, P; Demirtas, D; Droit, A; Guillemette, C; Hubmann, R; Jäger, U; Joly-Beauparlant, C; Labriet, A; Le, T; Lévesque, E; Rouleau, M; Schnabl, S; Shehata, M; Staber, PB; Tremblay, S; Turcotte, V; Vaillancourt, J; Vanura, K; Villeneuve, L | 1 |
| Anagnostopoulos, A; Chatzidimitriou, A; Galigalidou, C; Gemenetzi, K; Ghia, P; Ioannou, N; Iskas, M; Koravou, E; Kotouza, M; Kotta, K; Kouvatsi, A; Papazoglou, D; Pasentsis, K; Psomopoulos, F; Ramsay, AG; Scarfó, L; Stamatopoulos, K; Stavroyianni, N; Vardi, A; Vlachonikola, E | 1 |
| Ahn, IE; Fleisher, T; Gaglione, E; Lotter, J; Maric, I; Mu, R; Pittaluga, S; Pleyer, C; Rampertaap, S; Rosenzweig, S; Soto, S; Stetler-Stevenson, M; Sun, C; Superata, J; Tian, X; Wiestner, A; Yuan, CM | 1 |
| Burningham, Z; Chien, HC; Halwani, AS; Li, CY; Morreall, D; Passey, DG; Patil, V; Rasmussen, KM; Sauer, BC; Yong, CM | 1 |
| Ayala, A; Borthakur, G; Bose, P; Burger, J; Estrov, Z; Ferrajoli, A; Gandhi, V; Garg, N; Jabbour, E; Jain, N; Jorgensen, J; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Keating, M; Konopleva, M; Lopez, W; O'Brien, S; Patel, K; Pemmaraju, N; Plunkett, W; Sasaki, K; Takahashi, K; Thompson, P; Wang, S; Wang, W; Wang, X; Wierda, WG | 1 |
| Barr, PM; Barrientos, JC; Braggio, E; Cashen, AF; Coutre, SE; Erba, H; Hanson, CA; Kay, NE; Leis, JF; Lesnick, CE; Litzow, MR; Mato, AR; Mullane, MP; O'Brien, S; Paietta, EM; Shanafelt, TD; Singh, AK; Stone, R; Tallman, MS; Tschumper, RC; Wang, XV; Zhang, CC | 1 |
8 review(s) available for adenine and fludarabine
| Article | Year |
|---|---|
[Chronic lymphocytic leukemia].
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Piperidines; Practice Guidelines as Topic; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vidarabine; Vincristine | 2014 |
Novel treatments for chronic lymphocytic leukemia and moving forward.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Small Molecule Libraries; Sulfonamides; Vidarabine | 2014 |
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Drug Resistance, Neoplasm; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Nitrogen Mustard Compounds; Piperidines; Practice Patterns, Physicians'; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Vidarabine | 2014 |
A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Canada; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2015 |
Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Sulfonamides; Vidarabine | 2016 |
Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Vidarabine | 2018 |
Selecting Frontline Therapy for CLL in 2018.
Topics: Adenine; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Smith-Magenis Syndrome; Vidarabine | 2018 |
Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Neoplasm, Residual; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides; Vidarabine | 2020 |
5 trial(s) available for adenine and fludarabine
| Article | Year |
|---|---|
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunotherapy; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2019 |
Ibrutinib and rituximab for chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2019 |
A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Survival Rate; Vidarabine | 2020 |
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Prognosis; Survival Rate; Tumor Suppressor Protein p53; Vidarabine | 2021 |
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; Rituximab; Treatment Outcome; Vidarabine | 2021 |
22 other study(ies) available for adenine and fludarabine
| Article | Year |
|---|---|
Phosphorolytic cleavage of 2-fluoroadenine from 9-beta-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli. A pathway for 2-fluoro-ATP production.
Topics: Adenine; Adenosine; Adenosine Triphosphate; Animals; Binding, Competitive; Cell Line; Escherichia coli; Humans; Kidney; Kinetics; Leukemia; Liver; Mice; Phosphates; Purine Nucleosides; Rats; Vidarabine | 1987 |
2-fluoro-ATP: a toxic metabolite of 9-beta-D-arabinosyl-2-fluoroadenine.
Topics: Adenine; Adenosine Triphosphate; Animals; Arabinonucleotides; Cell Line; Chromatography, High Pressure Liquid; Leukemia P388; Leukemia, Experimental; Mice; Vidarabine | 1983 |
Preparation of a fludarabine intermediate via selective alkylation of 2-fluoroadenine.
Topics: Adenine; Alkylation; Arabinose; Nucleic Acid Conformation; Pentanols; Stereoisomerism; Vidarabine | 2006 |
Administration of fludarabine-loaded autologous red blood cells in simian immunodeficiency virus-infected sooty mangabeys depletes pSTAT-1-expressing macrophages and delays the rebound of viremia after suspension of antiretroviral therapy.
Topics: Adenine; Animals; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cercocebus atys; Drug Carriers; Erythrocytes; Female; Humans; Macrophages; Male; Myeloablative Agonists; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; STAT1 Transcription Factor; T-Lymphocyte Subsets; Tenofovir; Vidarabine; Viremia; Virus Replication | 2006 |
BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells.
Topics: Adenine; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Bcl-2-Like Protein 11; Beclin-1; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lysosomal-Associated Membrane Protein 2; Membrane Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Ubiquitin-Activating Enzymes; Vidarabine | 2013 |
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
Topics: Adenine; Antineoplastic Agents; Casein Kinase II; Drug Synergism; Hematologic Neoplasms; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthyridines; Phenazines; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Vidarabine | 2013 |
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Gene Expression Regulation, Leukemic; Humans; Immunotherapy; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Multivariate Analysis; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Rituximab; Treatment Outcome; Vidarabine | 2015 |
[Chronic lymphatic leukemia].
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Remission Induction; Rituximab; Vidarabine | 2015 |
Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer.
Topics: Adenine; Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sulfur Lyases; Cell Death; Cell Line, Tumor; Cytosine Deaminase; Docetaxel; Dose-Response Relationship, Drug; Enzymes; Flucytosine; Fluorouracil; Humans; Methanol; Molecular Targeted Therapy; Organoselenium Compounds; Pancreatic Neoplasms; Prodrugs; Purine-Nucleoside Phosphorylase; Recombinant Fusion Proteins; Selenomethionine; Taxoids; Tubulin Modulators; Vidarabine | 2015 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |
Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival.
Topics: Adenine; Aged; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Communication; Cell Survival; Cells, Cultured; Coculture Techniques; Cyclophosphamide; Cytokines; Drug Resistance, Neoplasm; Female; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mesenchymal Stem Cells; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Vidarabine | 2015 |
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; beta 2-Microglobulin; Bone Marrow; Case-Control Studies; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prognosis; Proportional Hazards Models; Pyrazoles; Pyrimidines; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2016 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cohort Studies; Disease Management; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Middle Aged; Neoplasm Invasiveness; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Retrospective Studies; Survival Analysis; Vidarabine | 2017 |
Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bayes Theorem; Chlorambucil; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Proportional Hazards Models; Pyrazoles; Pyrimidines; Vidarabine | 2017 |
Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Patient Selection; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides; Treatment Outcome; Vidarabine | 2019 |
Refining chemotherapy for chronic lymphocytic leukaemia with targeted drugs.
Topics: Adenine; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2019 |
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Databases, Factual; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; Vidarabine | 2019 |
Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease Management; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Smith-Magenis Syndrome; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine | 2020 |
UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Pharmacological; Female; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mass Spectrometry; Middle Aged; Minor Histocompatibility Antigens; NF-kappa B; Piperidines; Purines; Quinazolinones; Vidarabine | 2020 |
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clonal Evolution; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunological Synapses; Immunophenotyping; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Piperidines; Purines; Quinazolinones; Rituximab; T-Lymphocytes; Vidarabine | 2020 |
Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Chlorambucil; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Kaplan-Meier Estimate; Piperidines; Prednisone; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Rituximab; Treatment Outcome; Veterans; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2021 |